Cargando…
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
[Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing me...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2012
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469069/ https://www.ncbi.nlm.nih.gov/pubmed/23074541 http://dx.doi.org/10.1021/ml300172p |
_version_ | 1782246030031454208 |
---|---|
author | Dockendorff, Chris Nagiec, Marek M. Weïwer, Michel Buhrlage, Sara Ting, Amal Nag, Partha P. Germain, Andrew Kim, Han-Je Youngsaye, Willmen Scherer, Christina Bennion, Melissa Xue, Linlong Stanton, Benjamin Z. Lewis, Timothy A. MacPherson, Lawrence Palmer, Michelle Foley, Michael A. Perez, José R. Schreiber, Stuart L. |
author_facet | Dockendorff, Chris Nagiec, Marek M. Weïwer, Michel Buhrlage, Sara Ting, Amal Nag, Partha P. Germain, Andrew Kim, Han-Je Youngsaye, Willmen Scherer, Christina Bennion, Melissa Xue, Linlong Stanton, Benjamin Z. Lewis, Timothy A. MacPherson, Lawrence Palmer, Michelle Foley, Michael A. Perez, José R. Schreiber, Stuart L. |
author_sort | Dockendorff, Chris |
collection | PubMed |
description | [Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing metathesis step to form the macrocyclic ring. Varying the position of the macrocycle nitrogen and oxygen atoms provided inhibitors with improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC(50) of 0.4 μM against C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies with Patched knockout (Ptch(–/–)) cells and competition studies with the Smoothened (Smo) agonists SAG and purmorphamine demonstrate that in contrast to robotnikinin, select analogues are Smo antagonists. |
format | Online Article Text |
id | pubmed-3469069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | American
Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-34690692012-10-14 Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies Dockendorff, Chris Nagiec, Marek M. Weïwer, Michel Buhrlage, Sara Ting, Amal Nag, Partha P. Germain, Andrew Kim, Han-Je Youngsaye, Willmen Scherer, Christina Bennion, Melissa Xue, Linlong Stanton, Benjamin Z. Lewis, Timothy A. MacPherson, Lawrence Palmer, Michelle Foley, Michael A. Perez, José R. Schreiber, Stuart L. ACS Med Chem Lett [Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing metathesis step to form the macrocyclic ring. Varying the position of the macrocycle nitrogen and oxygen atoms provided inhibitors with improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC(50) of 0.4 μM against C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies with Patched knockout (Ptch(–/–)) cells and competition studies with the Smoothened (Smo) agonists SAG and purmorphamine demonstrate that in contrast to robotnikinin, select analogues are Smo antagonists. American Chemical Society 2012-08-30 /pmc/articles/PMC3469069/ /pubmed/23074541 http://dx.doi.org/10.1021/ml300172p Text en Copyright © 2012 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) |
spellingShingle | Dockendorff, Chris Nagiec, Marek M. Weïwer, Michel Buhrlage, Sara Ting, Amal Nag, Partha P. Germain, Andrew Kim, Han-Je Youngsaye, Willmen Scherer, Christina Bennion, Melissa Xue, Linlong Stanton, Benjamin Z. Lewis, Timothy A. MacPherson, Lawrence Palmer, Michelle Foley, Michael A. Perez, José R. Schreiber, Stuart L. Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies |
title | Macrocyclic Hedgehog Pathway
Inhibitors: Optimization
of Cellular Activity and Mode of Action Studies |
title_full | Macrocyclic Hedgehog Pathway
Inhibitors: Optimization
of Cellular Activity and Mode of Action Studies |
title_fullStr | Macrocyclic Hedgehog Pathway
Inhibitors: Optimization
of Cellular Activity and Mode of Action Studies |
title_full_unstemmed | Macrocyclic Hedgehog Pathway
Inhibitors: Optimization
of Cellular Activity and Mode of Action Studies |
title_short | Macrocyclic Hedgehog Pathway
Inhibitors: Optimization
of Cellular Activity and Mode of Action Studies |
title_sort | macrocyclic hedgehog pathway
inhibitors: optimization
of cellular activity and mode of action studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469069/ https://www.ncbi.nlm.nih.gov/pubmed/23074541 http://dx.doi.org/10.1021/ml300172p |
work_keys_str_mv | AT dockendorffchris macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT nagiecmarekm macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT weiwermichel macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT buhrlagesara macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT tingamal macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT nagparthap macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT germainandrew macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT kimhanje macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT youngsayewillmen macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT schererchristina macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT bennionmelissa macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT xuelinlong macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT stantonbenjaminz macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT lewistimothya macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT macphersonlawrence macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT palmermichelle macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT foleymichaela macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT perezjoser macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies AT schreiberstuartl macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies |